The DOI matches its Crossref record; 77 of the 79 references it cites were found in a registry or an index.
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Open accessAbstract
Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease that is closely linked both spatially and temporally to emergence of neurodegeneration and manifestation of clinical symptoms. There is an urgent need for accurate PET, CSF, and plasma biomarkers of tau pathology to improve the diagnostic process in clinical practice and the selection of participants and monitoring of treatment effects in trials.Recent developments Innovative second-generation tau-PET tracers with high affinity and selectivity to tau pathology in Alzheimer's disease have enabled detection of tau pathology in medial temporal lobe subregions that are affected in the earliest disease stages. Furthermore, novel but common tau spreading subtypes have been discovered using tau-PET, suggesting much greater interindividual differences in the distribution of tau pathology across the brain than previously assumed. In the CSF biomarker field, novel phosphorylated tau (p-tau) assays have been introduced that better reflect tau tangle load than established CSF biomarkers of tau pathology. The advent of cost-effective and accessible blood-based biomarkers for tau pathophysiology (ie, p-tau181, p-tau217, and p-tau231) might transform the Alzheimer's disease field, as these biomarkers correlate with post-mortem Alzheimer's disease pathology, differentiate Alzheimer's disease from other types of dementia, and predict future progression from normal cognition and mild cognitive impairment to Alzheimer's disease. In controlled investigational settings, improvements in tau-PET and biofluid p-tau markers have led to earlier disease detection, more accurate diagnostic methods, and refinement of prognosis. The anti-tau therapy landscape is rapidly evolving, with multiple ongoing phase 1 and 2 trials of post-translational modification of tau, tau immunotherapy, tau aggregation inhibitors, and targeting production of tau and reduction of intracellular tau levels. Neuroimaging and biofluid tau markers hold potential for optimising such clinical trials by augmenting participant selection, providing evidence of target engagement, and monitoring treatment efficacy. WHERE NEXT?: Major challenges to overcome are the high cost of tau-PET, partial sensitivity to detect early-stage Alzheimer's disease pathology, and off-target tracer binding. Prospective validation studies of biofluid p-tau markers are needed, and assay-related preanalytical and analytical factors need further refinement. Future studies should focus on demonstrating the diagnostic and prognostic accuracy of tau biomarkers-blood-based markers in particular-in non-tertiary settings, such as primary care, which is characterised by a diverse population with medical comorbidities. Large-scale head-to-head studies are needed across different stages of Alzheimer's disease to determine which tau biomarker is optimal in various clinical scenarios, such as early diagnosis, differential diagnosis, and prognosis, and for aspects of clinical trial design, such as proving target engagement, optimising participant selection, and refining monitoring of treatment effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it is crucial to find ways to reduce the need for PET scans due to their relative inaccessibility and costliness, while still preserving the ability to estimate the load and distribution of AD pathology as accurately and comprehensively. 12 , 13”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tau‐PET is often considered a state‐of‐the‐art outcome in AD research studies, a very accurate prognostic tool in patients with AD, and frequently used in clinical trials for AD during screening and to monitor treatment effects. 12 , 14 , 15 , 16”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a major component of NFTs, tau protein exhibits a spatial and temporal distribution that strongly correlates with clinical symptoms, making it a highly specific pathological biomarker in AD patients.152”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“Tau‐PET is often considered a state‐of‐the‐art outcome in AD research studies, a very accurate prognostic tool in patients with AD, and frequently used in clinical trials for AD during screening and to monitor treatment effects. 12 , 14 , 15 , 16”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Tau‐PET is often considered a state‐of‐the‐art outcome in AD research studies, a very accurate prognostic tool in patients with AD, and frequently used in clinical trials for AD during screening and to monitor treatment effects. 12 , 14 , 15 , 16”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
In the citing paper
“Plasma tau measurement could thus be used as a screening test in early-stage clinical trials to enrich trial participation with individuals more likely to have AD pathology (76, 77, 90).”
From All the Tau We Cannot See (2023) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationPET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214
Self-citationThe Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Self-citation
Cited by
Sorted by citations
Items 101–200 of 557
FDG‐PET markers of heterogeneity and different risk of progression in amnestic MCI
Caminiti, S., Francesco, S. D., Tondo, G., Galli, A., Redolfi, A., & Perani, D. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13385 · Cited by 27
Li, Z., Fan, Z., & Zhang, Q. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230799 · Cited by 27
Li, J., Song, J., Jia, L., Wang, M., Ji, X., Meng, R., & Zhou, D. (2024) · Biomolecules · doi:10.3390/biom14121519 · Cited by 28
Sulforaphane: An emerging star in neuroprotection and neurological disease prevention
Wu, N., Luo, Z., Deng, R., Zhang, Z., Zhang, J., Liu, S., Luo, Z., & Qi, Q. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116797 · Cited by 28
Kidney function and cognitive impairment: a systematic review and meta-analysis
Pei, X., Bakerally, N. B., Wang, Z., Bo, Y., Ma, Y., Yong, Z., Zhu, S., Gao, F., Bei, Z., & Zhao, W. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2463565 · Cited by 26
Chen, F., Wang, N., Tian, X., Su, J., Yan, Q., He, R., & He, X. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061568 · Cited by 25
Lee, H., Lee, H., Ma, Y., Eskandarian, L., Gaudet, K., Tian, Q., Krijnen, E. A., Russo, A. W., Salat, D. H., Klawiter, E. C., et al. (2024) · Aging Cell · doi:10.1111/acel.14267 · Cited by 24
Berberine modulates microglial polarization by activating TYROBP in Alzheimer's disease
Yu, Y., Wu, J., Jia, L., Feng, S., Qi, Z., Yu, H., Wu, Y., & Wang, S. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156237 · Cited by 24
Present and Future of Blood-Based Biomarkers of Alzheimer’s Disease: Beyond the Classics
Grigoli, M. M., Pelegrini, L. N. D. C., Whelan, R., & Cominetti, M. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148812 · Cited by 22
Roccati, E., Collins, J. M., Bindoff, A. D., Alty, J., Bartlett, L., King, A. E., & Vickers, J. C. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.06.018 · Cited by 21
Blood biomarkers and neurodegeneration in individuals exposed to repetitive head impacts
Bernick, C. B., Shan, G., Ritter, A. R., Ashton, N. J., Blennow, K., Lantero‐Rodriguez, J., Snellman, A., & Zetterberg, H. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01310-w · Cited by 23
Cáceres, C., Heusser, B., Garnham, A., & Moczko, E. (2023) · Cells · doi:10.3390/cells12232669 · Cited by 26
Unveiling the Significance of Peroxiredoxin 6 in Central Nervous System Disorders
Xue, M., Huang, X., Zhu, T., Zhang, L., Yang, H., Shen, Y., & Feng, L. (2024) · Antioxidants · doi:10.3390/antiox13040449 · Cited by 22
Liquid chromatography-tandem mass spectrometry in clinical laboratory protein measurement
Ma, Y., Wang, D., Li, H., Ma, X., Zou, Y., Mu, D., Yu, S., Cheng, X., & Qiu, L. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119846 · Cited by 22
Wang, J., Lu, X., & He, Y. (2025) · Biosensors · doi:10.3390/bios15020085 · Cited by 24
Endoplasmic reticulum stress in disease pathogenesis: its implications for therapy
Wei, S., Zhang, N., Zhang, H., Chen, Z., Li, S., Wu, W., Liu, Z., Xia, Z., Luo, P., & Cheng, Q. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02600-z · Cited by 25
Focused Ultrasound–mediated Liquid Biopsy in a Tauopathy Mouse Model
Pacia, C. P., Yuan, J., Yue, Y., Leuthardt, E. C., Benzinger, T. L. S., Nazeri, A., & Chen, H. (2023) · Radiology · doi:10.1148/radiol.220869 · Cited by 22
Sarto, J., Esteller, D., Guillén, N., Falgàs, N., Borrego‐Écija, S., Massons, M., Fernández‐Villullas, G., González, Y., Tort‐Merino, A., Bosch, B., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12897-5 · Cited by 23
An Anti-tau Therapeutic Antibody Etalanetug (E2814)
Rawal, S., Wildsmith, K. R., Aluri, J., Yagi, T., Chang, M., Niu, H., Zhou, J., Horie, K., Takahashi, E., Boyd, P., et al. (2025) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000680 · Cited by 21
Central Nervous System-Derived Extracellular Vesicles as Biomarkers in Alzheimer’s Disease
Yu, Y., Wang, Z., Chai, Z., Ma, S., Li, A., & Li, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178272 · Cited by 22
Tau kinetics in Alzheimer's disease
Hier, D. B., Azizi, S., Thimgan, M. S., & Wunsch, D. C. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1055170 · Cited by 22
Jiang, Y., Bian, W., Chen, J., Cao, X., Dong, C., Xiao, Y., Xu, B., & Sun, X. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12368 · Cited by 20
Han, X., Zhang, Y., Zhang, L., Zhang, L., & Wang, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117144 · Cited by 24
Biomarkers of mature neuronal differentiation and related diseases
Yuan, X., Li, W., Qi, Y., Ou, Y., Long, Q., & Zhang, P. (2024) · Future Science OA · doi:10.1080/20565623.2024.2410146 · Cited by 24
Zhang, M., Niu, H., Li, Q., Jiao, L., Li, H., & Wu, W. (2023) · Pharmaceuticals · doi:10.3390/ph17010038 · Cited by 20
Martínez‐Dubarbie, F., Guerra-Ruiz, A. R., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Infante, J., Pozueta‐Cantudo, A., García‐Martínez, M., Corrales‐Pardo, A., Bravo, M., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.152 · Cited by 18
Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease
Xia, Z.-D., Ma, R.-X., Wen, J.-F., Zhai, Y.-F., Wang, Y.-Q., Wang, F.-Y., Liu, D., Zhao, X.-L., Sun, B., Jia, P., et al. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230326 · Cited by 19
Identification of early Alzheimer’s disease subclass and signature genes based on PANoptosis genes
Wang, W., Lu, J., Pan, N., Zhang, H., Dai, J., Li, J. P., Chi, C., Zhang, L., Wang, L., & Zhang, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462003 · Cited by 21
Anijärv, T. E., Ossenkoppele, R., Smith, R. A., Binette, A. P., Collij, L. E., Behjat, H., Rittmo, J. Ö., Karlsson, L., Ahmadi, K., Strandberg, O. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63564-2 · Cited by 25
Self-citationDevanarayan, V., Charil, A., Horie, K., Doherty, T., Llano, D. A., Andreozzi, E., Sachdev, P., Ye, Y., Murali, L. K., Zhou, J., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14411 · Cited by 19
Tau proteins and senescent Cells: Targeting aging pathways in Alzheimer’s disease
Singh, M., Ali, H., Jyothi, S. R., Kaur, I., Kumar, S., Sharma, N., Prasad, G. V. S., Pramanik, A., Almalki, W. H., & Imran, M. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149165 · Cited by 18
Qi, X., Yuan, S., Ding, J., Sun, W., Shi, Y., Xing, Y., Liu, Z., Yao, Y., Fu, S., Sun, B., et al. (2024) · Aging Cell · doi:10.1111/acel.14352 · Cited by 18
Dolciotti, C., Righi, M., Grecu, E., Trucas, M., Maxia, C., Murtas, D., & Diana, A. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1553642 · Cited by 19
Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition
Drzezga, A. E., & Barthel, H. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270152 · Cited by 18
Does resveratrol improve cognition in humans? A scientometric study to an in‐depth review
Tu, W., Song, M., & Fan, X. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14276 · Cited by 18
Cao, J., Tang, Y., Chen, S., Yu, S., Wan, K., Yin, W., Zhen, W., Zhao, W., Zhou, X., Zhu, X., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231114 · Cited by 17
Pyroptosis in Alzheimer’s Disease: Mechanisms and Therapeutic Potential
Tang, T. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01579-5 · Cited by 17
Jin, Z., Lu, Y., Tang, H., & Cui, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70472 · Cited by 24
Guo, X., Liu, H. N., Song, Y., Wang, J., Liu, D., Zheng, Z., Li, J., Li, B., Song, A., He, W., et al. (2026) · MedComm · doi:10.1002/mco2.70497 · Cited by 26
Advanced brain imaging for the diagnosis of Alzheimer disease
Wang, Y.-T. T., Rosa‐Neto, P., & Gauthier, S. G. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001198 · Cited by 16
Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers
Kwon, H. S., Lee, E., Kim, H., Park, S., Park, H., Jeong, J. H., Koh, S., Choi, S. H., & Lee, J. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12502 · Cited by 17
Bisi, N., Pinzi, L., Rastelli, G., & Tonali, N. (2024) · Molecules · doi:10.3390/molecules29030722 · Cited by 17
Milán, J. A. S., Fernández‐Rhodes, M., Guo, X., Mulet, M., Ngan, S. C., Iyappan, R., Katoueezadeh, M., Sze, S. K., Serra, A., & Gallart‐Palau, X. (2023) · Aging Cell · doi:10.1111/acel.14062 · Cited by 15
Phytotherapy in Alzheimer’s Disease—A Narrative Review
Piekarz, J., Picheta, N., Burdan, O., Kurek, M., & Chrościńska–Krawczyk, M. (2024) · Biomedicines · doi:10.3390/biomedicines12081812 · Cited by 17
Gehlot, P., Pathak, R., Kumar, S., Choudhary, N. K., & Vyas, V. K. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117925 · Cited by 18
Giacomucci, G., Crucitti, C., Ingannato, A., Moschini, V., Bagnoli, S., Pozzi, F. E., Marcantelli, E., Padiglioni, S., Morinelli, C., Mazzeo, S., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70116 · Cited by 19
Targeted degradation of α-synuclein by arginine-based PROTACs
Shen, L., Zhang, J., Wang, Z., Liu, Y., Cui, S., & Rao, H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110449 · Cited by 18
Anti-inflammatory effect of curcumin on neurological disorders: a narrative review
Zhou, B., & Hu, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1658115 · Cited by 19
Ferroptosis: A new strategy for targeting Alzheimer’s disease
Qiang, R. R., Xiang, Y., Zhang, L., Bai, X. Y., Zhang, D., Li, Y. J., Yang, Y. L., & Liu, X. L. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105773 · Cited by 15
Changes in Alzheimer's disease blood biomarkers in kidney failure before and after kidney transplant
Blankenship, A. E., Yoksh, L., Kueck, P. J., Mahnken, J. D., Morris, J. K., & Gupta, A. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12614 · Cited by 15
Peng, L., Zhang, Z., Li, Q., Song, Z., Yan, C., & Ling, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39217 · Cited by 18
Li, P., Yang, L., Shao, X., Zou, Z., Shi, H., Sun, Y., Wu, X., Li, Z., Li, Y., & Li, Z. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128276 · Cited by 14
Zhang, Y. C., Li, Z., Guan, H., Qiu, Z., & Zou, C. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70548 · Cited by 17
Artificial intelligence driven protein design and sustainable nanomedicine for advanced theranostics
Esmaeilpour, D., Hamblin, M. R., Cheng, J., Khosravi, A., Liu, J., Zarepour, A., Zarrabi, A., Sillanpaa, M., Zare, E. N., Shen, J., et al. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.01.036 · Cited by 18
González, A., Calfío, C., Lüttges, V., González-Madrid, A., & Guzmán, C. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230150 · Cited by 14
Identify biological Alzheimer’s disease using a novel nucleic acid–linked protein immunoassay
Wang, Y., Ashton, N. J., Therriault, J., Benedet, A. L., Macedo, A. C., Pola, I., Aumont, É., Molfetta, G. D., Arias, J. F., Tan, K., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcaf004 · Cited by 14
Long non‐coding RNAs as key regulators of neurodegenerative protein aggregation
Xu, Q., Liu, D., Zhu, L., Su, Y., & Huang, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14498 · Cited by 15
Zhan, X., Wen, G., Wu, X., & Li, J. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00490-9 · Cited by 14
ApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease
Lennol, M. P., Bordier, C., Kamelher, L., Ulrich, J. D., Holtzman, D. M., & Gratuze, M. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250965 · Cited by 14
Precision medicine in neurodegeneration: the IHI-PROMINENT project
Tate, A., Suárez‐Calvet, M., Ekelund, M., Eriksson, S., Eriksdotter, M., van der Flier, W. M., Georges, J., Kivipelto, M., Kramberger, M. G., Lindgren, P., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1175922 · Cited by 13
Wang, H., Ma, L., Sheng, Z.-H., Liu, J.-Y., Yuan, W.-Y., Guo, F., Zhang, W., & Tan, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1256389 · Cited by 13
Time‐encoded ASL reveals lower cerebral blood flow in the early AD continuum
Falcón, C., Montesinos, P., Václavů, L., Kassinopoulos, M., Minguillón, C., Fauria, K., Cascales‐Lahoz, D., Contador, J., Fernández‐Lebrero, A., Navalpotro‐Gómez, I., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14059 · Cited by 13
Advance and Prospect of Positron Emission Tomography in Alzheimer’s disease research
Wang, Y., Liao, W., Wang, L., Li, J., Huang, D., Cheng, W., Tian, J., & Luan, P. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03081-2 · Cited by 13
Nano-imaging agents for brain diseases: Environmentally responsive imaging and therapy
Liang, F., You, Q., Ma, X., Wang, H., Wang, C., He, Z., Yang, Y., & Zhu, L. (2023) · Nano Research · doi:10.1007/s12274-023-6149-1 · Cited by 13
Ge, R., Chen, M., Li, Q., Liu, M., Zhou, J., & Xie, S. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01538-2 · Cited by 13
Translating Alzheimer’s Disease Mechanisms into Therapeutic Opportunities
Li, J., Wang, L., Zhang, X., Shi, J., Zhu, Y. Z., Wang, H., Zhu, X., Zhu, Q., & Luo, J. (2025) · Biomolecules · doi:10.3390/biom15091290 · Cited by 13
Peripheral immune and metabolic regulation of Aβ and Tau by exercise in Alzheimer’s disease
Yu, Y., & Chen, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1678526 · Cited by 14
Tau in Alzheimer's disease: Shaping the future patient journey
Mummery, C. J., Li-Hsian, C. C., Lasagna‐Reeves, C. A., Ossenkoppele, R., Rowe, C. C., Scharre, D. W., Wang, H., Kyaga, S., & Cummings, J. L. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100447 · Cited by 15
Self-citationTherapeutic targeting of neuroimmune mechanisms in neurodegeneration
Monroe, K. M., Hong, S. Y., Lewcock, J. W., & Yang, A. C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01370-7 · Cited by 16
Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s
Salvadó, G., Horie, K., Barthélemy, N. R., Vogel, J. W., Binette, A. P., Chen, C. D., Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Holtzman, D. M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.075367 · Cited by 14
Self-citationDiagnosis of Alzheimer's disease: Towards accuracy and accessibility
Mu, Y., Chang, K., Chen, Y.-F., Yan, K., Wang, C.-X., & Hua, Q. (1970) · Journal of Biological Methods · doi:10.14440/jbm.2024.412 · Cited by 13
Zhao, W., Zhang, W. Y., Hu, Y., Zhou, Y., Zhao, J., Li, Y., & Xu, Z. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04162-4 · Cited by 12
Song, Y., Dai, C., Shinohara, M., Tung, Y. C., Zhou, S., Huang, W., Seffouh, A., Luo, Y., Willadsen, M., Jiao, Y., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.08.028 · Cited by 13
Biofluid biomarkers for Alzheimer’s disease: past, present, and future
An, C., Cai, H., Ren, Z., Fu, X., Quan, S., & Jia, L. (2024) · Medical Review · doi:10.1515/mr-2023-0071 · Cited by 14
Lane‐Donovan, C., Smith, A. W., Saloner, R., Miller, B. L., Casaletto, K. B., & Kao, A. W. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70320 · Cited by 12
León-Arcia, K., Andrade-Guerrero, J., Martínez-Orozco, H., Villegas-Rojas, M. M., Pérez-Segura, I., Ramírez, I. L., Vilches‐Flores, A., Guerra‐Crespo, M., Díaz-Miranda, S. Y., & Soto-Rojas, L. O. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102918 · Cited by 14
Leiris, N. D., Perret, P., Lombardi, C., Gözel, B., Chierici, S., Millet, P., Debiossat, M., Bacot, S., Tournier, B. B., Chames, P., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04987-1 · Cited by 10
Rizzi, L., & Grinberg, L. T. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01744-9 · Cited by 12
Microglial ApoD ‐induced NLRC4 inflammasome activation promotes Alzheimer's disease progression
Yu, Y., Lv, J., Ma, D., Han, Y., Zhang, Y., Xu, P., Wang, Z., & Wang, Z. (2024) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12361 · Cited by 12
Sun, Y., Liu, C., & He, L. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0455 · Cited by 13
Doroszkiewicz, J., Kulczyńska‐Przybik, A., Dulewicz, M., Mroczko, J., Borawska, R., Słowik, A., Zetterberg, H., Hanrieder, J., Blennow, K., & Mroczko, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147543 · Cited by 13
Rathee, S., Sen, D., Pandey, V., & Jain, S. (2024) · Current Drug Targets · doi:10.2174/0113894501320096240627071400 · Cited by 16
Lin, X., Chen, C., Chen, J., Zhu, C., Zhang, J., Su, R., Chen, S., Weng, S., Chang, X., Lin, S., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c05249 · Cited by 11
Gérard, T., Colmant, L., Malotaux, V., Salman, Y., Huyghe, L., Quenon, L., Boyer, E., Dricot, L., Ivanoiu, A., Lhommel, R., et al. (2025) · European Journal of Neurology · doi:10.1111/ene.70068 · Cited by 13
New Approaches to the Treatment of Alzheimer’s Disease
Kruk-Słomka, M., Kuceł, D., Małysz, M., Machnikowska, A., Orzelska‐Górka, J., & Biała, G. (2025) · Pharmaceuticals · doi:10.3390/ph18081117 · Cited by 12
Coley, N., Zetterberg, H., Cantet, C., Guyonnet, S., Ashton, N. J., Vellas, B. J., Blennow, K., Andrieu, S., Vellas, B. J., Guyonnet, S., et al. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00255-6 · Cited by 11
Cheng, Y., Lin, L., Huang, P., Zhang, J., Wang, Y., & Pan, X. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003103 · Cited by 10
Chen, X., Yang, S., Shao, H., Wang, S., Xie, J., Liu, Q., Huang, Y., Gan, N., & Huang, S. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.155897 · Cited by 10
Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementia
Cody, K. A., Du, L., Studer, R., Jonaitis, E. M., Asthana, S., Christian, B. T., Chin, N. A., Kirmess, K. M., Meyer, M. R., Yarasheski, K. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14570 · Cited by 11
Ding, H., Lyu, C., Karjadi, C., Sunderaraman, P., Young, C. B., Mormino, E. C., Low, S., Devine, S., Gifford, K. A., Au, R., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-95852-8 · Cited by 11
Tang, P., Zhao, D., Lin, H., Li, X., Shi, C., Li, P., & Chen, H. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115489 · Cited by 11
Fei, Z., Pan, B., Pei, R., Ye, S., Wang, Z., Ma, L., Zhang, R., Li, C., Du, X., & Cao, H. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.56 · Cited by 11
Emmerson, J. T., Carmo, S. D., Liu, Y., Shalhoub, A., Ai, L., Bonomo, Q., Malcolm, J. C., Breuillaud, L., & Cuello, A. C. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106227 · Cited by 11
Blood and Cerebrospinal Fluid Biomarkers in Vascular Dementia and Alzheimer’s Disease
Gorelick, P. B. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.08.001 · Cited by 11
Ossenkoppele, R., Salvadó, G., Janelidze, S., Binette, A. P., Bali, D., Karlsson, L., Palmqvist, S., Mattsson, N., Stomrud, E., Therriault, J., et al. (2024) · medRxiv · doi:10.1101/2024.06.12.24308824 · Cited by 10
Self-citationYu, Y.-T., Lin, H., Chen, X., Sun, M., Wei, C., Xue, M.-F., Gao, Y., Tang, W., Zheng, C.-Y., Li, S., et al. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.105924 · Cited by 11
Wu, L., Sun, Y., Yin, Y., Wu, Z., Liu, R., Liu, Y., Zhu, Y., Shao, M., Zhou, H., Lu, C., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119017 · Cited by 9
Álvarez‐Sánchez, L., Peña‐Bautista, C., Ferré‐González, L., Balaguer, Á., Amengual, J. L., Baquero, M., & Cháfer‐Pericás, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-01511-3 · Cited by 9
Sha, D., Zhang, J., Xu, F., Wang, X., He, X., & Shu, X. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1595847 · Cited by 9
Jeon, S. Y., Wang, S., Roh, H. W., Kim, K. Y., Chang, Y. Y., Kim, E., Bae, J. N., & Ryu, S. (2025) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e215 · Cited by 9
Metadata
- Authors
- Ossenkoppele, R., van der Kant, R., & Hansson, O.
- Affiliations
- Lund University (SE)
- Corresponding author
- Ossenkoppele, Rik
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 21
- Issue
- 8
- Pages
- 726-734
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W4281564421
- Cited by
- 557
- References
- 79
- Citations by year
- 2026: 127 · 2025: 174 · 2024: 142 · 2023: 98 · 2022: 15
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- VU Research Portal (publishedVersion, other-oa)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau pathology, tau biomarkers, tau PET tracers, phosphorylated tau, cerebrospinal fluid biomarkers, blood-based biomarkers, anti-tau therapy, clinical trial participant selection, early disease detection, tau immunotherapy, tau aggregation inhibitors, dementia diagnosis, mild cognitive impairment, primary care
- MeSH terms
- Alzheimer Disease, Brain, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neuroimaging, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
